2023
A Patient with an Unusual Cause of AKI and Scrotal Swelling
Gomez D, Perazella M. A Patient with an Unusual Cause of AKI and Scrotal Swelling. Kidney360 2023, 4: 1188-1189. PMID: 37651667, PMCID: PMC10484347, DOI: 10.34067/kid.0000000000000125.Peer-Reviewed Original Research
2015
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosis
2010
Experience with outpatient computed tomographic-guided renal biopsy.
Margaryan A, Perazella MA, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided renal biopsy. Clinical Nephrology 2010, 74: 440-5. PMID: 21084047, DOI: 10.5414/cnp74440.Peer-Reviewed Original ResearchConceptsNative kidney biopsiesKidney biopsyRenal biopsyPost-biopsy observation periodInpatient observation periodObservation periodLow complication rateTime of admissionYale-New Haven Medical CenterDuration of procedureInstances of deathHemoglobin concentration changesDetectable bleedingSerum creatinineComplication rateMean ageRenal sizeAdequate tissueMedical CenterOutpatient unitDiagnostic tissueBiopsyLaboratory dataTransfusionPatients
2004
Fellows’ Forum in Dialysis. Depression: A Common but Underrecognized Condition Associated with End‐Stage Renal Disease
Perazella M, Wang P, Watnick S. Fellows’ Forum in Dialysis. Depression: A Common but Underrecognized Condition Associated with End‐Stage Renal Disease. Seminars In Dialysis 2004, 17: 237-241. PMID: 15144552, DOI: 10.1111/j.0894-0959.2004.17313.x.Peer-Reviewed Original ResearchUse of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDisease
2003
Nephrogenic Fibrosing Dermopathy: An Unusual Skin Condition Associated with Kidney Disease
Perazella MA, Ishibe S, Perazella MA, Reilly RF. Nephrogenic Fibrosing Dermopathy: An Unusual Skin Condition Associated with Kidney Disease. Seminars In Dialysis 2003, 16: 276-280. PMID: 12753692, DOI: 10.1046/j.1525-139x.2003.16053.x.BooksConceptsCommon patient complaintLong-term hemodialysisNephrogenic fibrosing dermopathyCorticosteroid therapyInflammatory cellsKidney diseasePatient complaintsMucin depositsSkin biopsiesSpindle cellsSkin disordersFibroblast-type cellsReticular dermisCollagen bundlesInternal organsIncreased numberHemodialysisPatientsSclerodermaDisordersCellsDysesthesiaPruritusBiopsyDysfunction
2001
Indinavir nephropathy revisited: A pattern of insidious renal failure with identifiable risk factors
Reilly R, Tray K, Perazella M. Indinavir nephropathy revisited: A pattern of insidious renal failure with identifiable risk factors. American Journal Of Kidney Diseases 2001, 38: e23.1-e23.6. PMID: 11576910, DOI: 10.1053/ajkd.2001.27732.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusRenal failureSerum creatinineRisk factorsDiffuse interstitial infiltratesElevated serum creatinineAcute renal failureIdentifiable risk factorsProgressive tubulointerstitial injuryIndinavir therapyFlank painHepatitis CTubulointerstitial injuryTubulointerstitial lesionsPositive patientsRenal injuryRenal biopsyInterstitial infiltratesImmunodeficiency virusNumerous eosinophilsFocal necrosisRenal syndromeProgressive riseIndinavirPotential mechanismsTreatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate
Alappan R, Cruz D, Abu-Alfa A, Mahnensmith R, Perazella M. Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate. American Journal Of Kidney Diseases 2001, 37: 294-299. PMID: 11157369, DOI: 10.1053/ajkd.2001.21292.Peer-Reviewed Original ResearchConceptsHigh dialysate calcium concentrationSevere intradialytic hypotensionDialysate calcium concentrationIntradialytic hypotensionBlood pressureEnd-stage renal disease populationCalcium concentrationLow dialysate calciumSeverity of hypotensionMean arterial pressurePeripheral vascular resistanceIntradialytic blood pressureRenal disease populationProspective crossover studyTreatment of patientsMultiple pathogenic factorsType of therapyDialysate calciumHemodynamic instabilityVascular resistanceHemodynamic stabilityArterial pressureCrossover studyCardiac outputCool dialysate
2000
Drug-induced hyperkalemia: old culprits and new offenders
Perazella M. Drug-induced hyperkalemia: old culprits and new offenders. The American Journal Of Medicine 2000, 109: 307-314. PMID: 10996582, DOI: 10.1016/s0002-9343(00)00496-4.Peer-Reviewed Original ResearchConceptsDrug-induced hyperkalemiaRisk of hyperkalemiaRenal potassium excretionRenal impairmentPatient characteristicsPotassium excretionPotassium handlingPotassium loadPrescribed medicationsExcessive ingestionHyperkalemiaCounter drugsOld culpritsNutritional supplementsPotassium homeostasisMedicationsPatientsDrugsCellular uptakeInfusionAbnormalitiesExcretionPhysiciansImpairmentIngestionAce inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitorsAre selective COX-2 inhibitors nephrotoxic?
Perazella M, Eras J. Are selective COX-2 inhibitors nephrotoxic? American Journal Of Kidney Diseases 2000, 35: 937-940. PMID: 10793030, DOI: 10.1016/s0272-6386(00)70266-6.Peer-Reviewed Original ResearchConceptsHigh-risk patientsRenal insufficiencySelective cyclooxygenase-2 enzyme inhibitorsSuch high-risk patientsNonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsChronic renal impairmentChronic renal insufficiencyAcute renal failureAcute renal insufficiencyAdverse gastrointestinal effectsCyclooxygenase-2 enzyme inhibitorsAnti-inflammatory drugsCourse of therapyCOX-2 inhibitorsPain syndromeRenal impairmentRenal failureGastrointestinal effectsNephrotoxic potentialInflammatory diseasesEnzyme inhibitorsPatientsInsufficiencyInhibitors
1999
Trimethoprim-Sulfamethoxazole Therapy in Outpatients: Is Hyperkalemia a Significant Problem?
Alappan R, Buller G, Perazella M. Trimethoprim-Sulfamethoxazole Therapy in Outpatients: Is Hyperkalemia a Significant Problem? American Journal Of Nephrology 1999, 19: 389-394. PMID: 10393376, DOI: 10.1159/000013483.Peer-Reviewed Original ResearchConceptsSerum potassium concentrationSerum creatinine levelsTrimethoprim-sulfamethoxazole therapyBaseline serum potassium concentrationVariety of infectionsCreatinine levelsDay 5Treatment groupsPotassium concentrationControl groupMean serum potassium concentrationBlood urea nitrogen levelsDevelopment of hyperkalemiaLife-threatening hyperkalemiaMild renal insufficiencyDays of therapyHigher serum potassium concentrationsImmunodeficiency syndrome (AIDS) patientsUrea nitrogen levelsSerum glucose concentrationRelevant hyperkalemiaOral antibioticsRenal insufficiencyMost patientsSevere hyperkalemiaMidodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. American Journal Of Kidney Diseases 1999, 33: 920-926. PMID: 10213650, DOI: 10.1016/s0272-6386(99)70427-0.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionPost-HD blood pressuresIntradialytic blood pressureIntradialytic hypotensionBlood pressureEffective therapyLaboratory valuesCombination therapy phaseConsecutive HD treatmentsProspective crossover studyBlood pressure measurementsKt/VVolume of salineControl phaseAlpha1 agonistHypotensive symptomsMorbid complicationCrossover studyUseful therapyProspective studyNursing interventionsHD treatmentMidodrineTreatment phaseTherapy phaseExtreme Hyperphosphatemia and Acute Renal Failure after a Phosphorus-Containing Bowel Regimen
Orias M, Mahnensmith R, Perazella M. Extreme Hyperphosphatemia and Acute Renal Failure after a Phosphorus-Containing Bowel Regimen. American Journal Of Nephrology 1999, 19: 60-63. PMID: 10085452, DOI: 10.1159/000013427.Peer-Reviewed Case Reports and Technical NotesConceptsAcute renal failureRenal failureOliguric acute renal failureBowel-cleansing preparationsBowel-cleansing regimenBowel regimenExtreme hyperphosphatemiaHypocalcemic tetanyGastrointestinal proceduresRenal excretionGastrointestinal transitPatientsIntoxicationRegimenFailureHyperphosphatemiaRegimensExcretionDiseaseTetanyRinger's lactate: An inexpensive and effective dialysate for continuous renal replacement therapy
Perazella M, Cruz D. Ringer's lactate: An inexpensive and effective dialysate for continuous renal replacement therapy. American Journal Of Kidney Diseases 1999, 33: 614-615. PMID: 10070931, DOI: 10.1016/s0272-6386(99)70206-4.Peer-Reviewed Original Research
1998
Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria.
Perazella M, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clinical Nephrology 1998, 50: 194-6. PMID: 9776425.Peer-Reviewed Original ResearchConceptsRenal biopsy findingsRenal insufficiencyBiopsy findingsMild renal insufficiencyAcute renal failureIndinavir crystalsIndinavir therapyRenal failureAntiretroviral agentsUrinary obstructionAIDS patientsCellular castsPatientsPyuriaInsufficiencyRecent reportsSmall percentDiscontinuationNephropathyMedicationsSecond caseDiuresisNephrolithiasisIndinavirObstructionReduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol
Cayco A, Abu-Alfa A, Mahnensmith R, Perazella M. Reduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol. American Journal Of Kidney Diseases 1998, 32: 302-308. PMID: 9708617, DOI: 10.1053/ajkd.1998.v32.pm9708617.Peer-Reviewed Original ResearchConceptsDynamic venous pressureHistorical control groupVenous pressureArteriovenous graftsSurveillance protocolStudy groupBlood flow rateThrombosis rateControl groupSimilar historical control groupHemodialysis vascular accessSynthetic arteriovenous graftsLower thrombosis rateML/minGraft impairmentVenous stenosisHD sessionVascular accessVascular stenosisPatientsScreening testStenosisStudy periodFrustrating problemConsecutive readingsMidodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clinical Nephrology 1998, 50: 101-7. PMID: 9725781.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionIntradialytic hypotensionMidodrine therapyHD sessionSafe therapyEnd-stage renal disease patientsStage renal disease patientsAlpha-1 adrenergic agonistMean ultrafiltration volumeSignificant causative roleRenal disease patientsTreatment-related factorsPatient-specific factorsMost therapeutic interventionsKt/VHypotensive symptomsBlood pressureHemodialysis patientsHD patientsDisease patientsSubjective improvementAdverse reactionsFrustrating complicationMean albuminSafe treatmentA Boy with Headache, Fatigue, and Weakness
Perazella M. A Boy with Headache, Fatigue, and Weakness. Hospital Practice 1998, 33: 193-196. PMID: 9562842, DOI: 10.1080/21548331.1998.11443680.Peer-Reviewed Original Research
1997
Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients?
Cruz D, Mahnensmith R, Perazella M. Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients? American Journal Of Kidney Diseases 1997, 30: 772-779. PMID: 9398120, DOI: 10.1016/s0272-6386(97)90081-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdrenergic alpha-AgonistsAgedAged, 80 and overBlood PressureDiastoleDizzinessFatigueFemaleFollow-Up StudiesHumansHypotensionKidney Failure, ChronicLongitudinal StudiesMaleMiddle AgedMidodrineMuscle CrampMuscle WeaknessParesthesiaProspective StudiesPulseRenal DialysisRisk FactorsSafetyScalpSystoleConceptsDiastolic blood pressureSystolic blood pressureBlood pressureMidodrine therapyArterial pressureHemodialysis patientsIntradialytic hypotensionPulse rateEnd-stage renal disease patientsIntradialytic systolic blood pressureEfficacy of midodrineSymptomatic hemodialysis patientsNeurogenic orthostatic hypotensionMean arterial pressureRenal disease patientsAdequate patient numbersBlood pressure measurementsAlpha-adrenergic agonist activityConsecutive dialysis sessionsAutonomic dysfunctionDialysis hypotensionOral agentsOrthostatic hypotensionSymptomatic hypotensionProspective trial